Introduction

Obstructive sleep apnea (OSA) and snoring represent highly prevalent conditions affecting millions of adults worldwide, with OSA alone affecting an estimated 10-17% of the adult population. The primary pathophysiology involves collapse of the upper airway during sleep, producing intermittent oxygen desaturation and sleep fragmentation with associated daytime somnolence, cognitive dysfunction, and elevated cardiovascular disease risk. While continuous positive airway pressure (CPAP) therapy remains the gold standard treatment with strongest evidence base, many patients demonstrate intolerance to CPAP masks, leading to non-compliance and continuation of untreated OSA.

Dental appliances offer effective alternative or adjunctive treatment for snoring and OSA, with demonstrated efficacy comparable to CPAP in mild-to-moderate disease and utility as adjunctive therapy in severe disease. Mandibular advancement devices (MADs) and tongue-retaining devices represent the primary appliance categories, with extensive research documenting their mechanism of action, efficacy, and side effect profiles. Understanding these appliance types, their indications, and their clinical application positions dental practitioners as essential members of the sleep medicine treatment team.

Understanding the anatomical and physiological mechanisms underlying snoring and OSA is essential for appreciating how dental appliances modify these processes. During wakefulness, active muscle tone maintains upper airway patency even in individuals with anatomically narrow airways. During sleep, however, muscle tone decreases, allowing passive airway narrowing in susceptible individuals.

The upper airway exists as a collapsible tube whose patency depends on a balance between intraluminal pressure (positive pressure tending to open the airway) and surrounding tissue pressures (tending to collapse the airway). In individuals with normal anatomy and muscle tone, this balance maintains airway patency throughout sleep. However, in individuals with anatomically narrow airway (from tonsillar hypertrophy, adenoid enlargement, soft palate redundancy, large tongue, micrognathia, or other factors) or muscle dysfunction, this balance is precarious.

Snoring results from vibration of relaxed pharyngeal tissues as air passes through partially narrowed airway. Obstructive sleep apnea occurs when partial or complete airway collapse produces either oxygen desaturation or arousal from sleep. The repetitive oxygen desaturations and sleep arousals characteristic of untreated OSA produce nocturnal hypoxemia, sleep fragmentation, and activation of sympathetic nervous system, ultimately contributing to hypertension, coronary artery disease, stroke, and sudden cardiac death.

Mandibular Advancement Devices: Mechanism of Action

Mandibular advancement devices (MADs) represent the most extensively researched and widely used dental appliances for sleep apnea treatment. These appliances, also termed mandibular repositioning appliances or oral mandibular advancement devices, function by forward positioning of the mandible relative to the maxilla. This forward positioning accomplishes multiple beneficial effects on upper airway geometry and function:

Direct airway expansion: Forward mandibular positioning directly increases the anterior-posterior dimension of the oropharynx, increasing airway cross-sectional area and reducing air velocity through narrowed segments. The magnitude of airway expansion correlates with the amount of mandibular advancement, with greater forward positioning producing proportionally greater airway enlargement. Tongue base repositioning: Since the tongue attaches to the mandible via the genioglossus muscle, forward mandibular positioning mechanically pulls the tongue base forward, away from the posterior pharyngeal wall. This anterior tongue positioning increases the oropharyngeal space and eliminates the tongue base as a source of airway obstruction. Soft palate tension: Forward mandibular positioning increases tension on the soft palate and palatopharyngeal muscles, stiffening these structures and reducing their propensity for collapse during sleep. Hyoid bone repositioning: The hyoid bone, suspended by muscular attachments including connections to the mandible, is pulled anteroinferiorly by forward mandibular positioning. This hyoid repositioning enlarges the hypopharyngeal airway segment.

The net effect of these multiple mechanisms is substantial expansion of the upper airway cross-sectional area in most individuals wearing properly positioned mandibular advancement appliances. This airway expansion reduces both snoring (by eliminating turbulent airflow and tissue vibration) and apneic episodes (by maintaining airway patency during sleep).

Mandibular Advancement Device Types and Design

Multiple MAD designs exist, differing in construction method (custom versus prefabricated), degree of mandibular advancement (fixed versus titratable), and material composition. Custom appliances fabricated from patient dental impressions generally provide superior comfort, fit, and retention compared to prefabricated devices, making them preferred for long-term management.

Titratable MADs allow gradual forward positioning of the mandible to find optimal therapeutic position while minimizing side effects. Rather than achieving maximum mandibular advancement at device insertion, titratable appliances begin at modest advancement with subsequent increases at periodic follow-up appointments. This gradual titration approach allows adaptation of temporomandibular joint (TMJ) structures and muscles while identifying minimum advancement necessary for therapeutic effect.

The mechanism of mandibular advancement in titratable devices varies. Some designs incorporate screw mechanisms activated at follow-up appointments by the practitioner, moving the mandible incrementally forward. Other designs employ elastic mechanisms allowing patient-controlled gradual advancement. The choice between practitioner-controlled and patient-controlled titratable designs involves trade-offs between precision and patient compliance.

Tongue-Retaining Devices

While mandibular advancement devices represent the most common dental appliance approach to OSA, tongue-retaining devices (TRDs) offer alternative mechanism based on anterior positioning of the tongue through suction rather than mandibular advancement. These devices consist of a small chamber that encases the tongue tip, with a vacuum mechanism that gently pulls the tongue forward during sleep.

Tongue-retaining devices provide advantages in specific patient populations, particularly those with extensive prior dental treatment (crowns, implants, dentures) that might be affected by mandibular advancement devices, or those with limited mandibular mobility (TMJ disorder, trismus) precluding mandibular movement. Some patients unable to tolerate MADs demonstrate adequate response to tongue-retaining devices.

The efficacy of tongue-retaining devices appears somewhat lower than well-fitted mandibular advancement devices for moderate to severe OSA, though they perform comparably to MADs in mild disease and snoring. Research suggests variable patient response, with some patients achieving excellent therapeutic response while others show minimal improvement. The reason for this variability remains incompletely understood.

Palatal Implants and Alternative Approaches

Palatal implants (typically small rod-shaped devices placed in the soft palate) represent alternative approach to snoring reduction through mechanisms including tissue stiffening and inflammation-mediated scar formation that reduces soft palate flaccidity. While effective for simple snoring, their efficacy for OSA is limited, making them less preferred than MADs or tongue-retaining devices.

Radiofrequency ablation of soft palate tissues similarly reduces snoring through tissue tightening, with variable efficacy for OSA. These procedures lack the evidence base of dental appliances and are generally reserved for patients unable or unwilling to use dental appliances.

Efficacy: Evidence from Controlled Trials

The efficacy of mandibular advancement devices has been demonstrated in multiple controlled trials and meta-analyses. Studies comparing MADs to placebo or no treatment document substantial reductions in apnea-hypopnea index (AHI, the standard measure of sleep apnea severity) and improvements in sleep architecture, oxygen saturation, and daytime somnolence. The magnitude of improvement varies among patients, with some achieving complete resolution of sleep apnea (AHI reduction to <5 events per hour) while others show partial improvement.

Meta-analytic data indicates that mandibular advancement devices reduce AHI by approximately 50% on average, with some patients showing greater improvement and others showing modest response. The variability in response relates to factors including baseline anatomical airway obstruction severity, amount of mandibular advancement achieved, patient compliance with nightly appliance use, and individual anatomical factors determining MAD efficacy.

Direct comparison trials between MADs and CPAP therapy show comparable efficacy in mild-to-moderate OSA (AHI <30), with CPAP potentially superior in severe disease. However, patient compliance often favors MADs, as they are simpler to use, less intrusive, and better tolerated than nasal masks, potentially resulting in superior real-world efficacy despite similar laboratory-measured efficacy.

Combination Therapy: MAD Plus CPAP

For patients with severe OSA inadequately controlled with CPAP or MAD monotherapy, combination therapy employing both devices may achieve better results than either alone. This approach is particularly useful for patients unable to tolerate full therapeutic CPAP pressures, who can achieve partial pressure reduction with MAD while using lower CPAP pressures. The combination of devices often improves tolerance and compliance while maintaining therapeutic efficacy.

Side Effects and Adverse Effects

Long-term mandibular advancement device use can produce several adverse effects, particularly with devices using fixed mandibular advancement rather than titratable designs. Common side effects include:

Temporomandibular joint symptoms: Jaw pain, clicking, or joint dysfunction occurs in a minority of patients, generally mild and diminishing over time. Proper appliance fit and gradual titration minimize TMJ effects. Dental changes: Long-term MAD use can produce reversible changes in mandibular position and bite, particularly in patients with primary dentition or young adults with incomplete skeletal maturation. These changes are generally minor and reverse after discontinuation of device use. Sleep-related bruxism exacerbation: Some patients demonstrate increased teeth grinding during sleep with appliance use, requiring use of protective overlays or appliance modification. Anterior open bite development: Rarely, long-term MAD use produces anterior open bite (lack of tooth contact in anterior region), presumably from mandibular adaptation to chronic forward positioning. This effect is more common with older appliance designs and less common with modern titratable approaches. Gum inflammation and teeth sensitivity: Proper device cleaning and maintenance minimize inflammation. Patient education regarding appliance hygiene is essential.

Most side effects are mild and reversible with appliance adjustment, discontinuation, or combination with other treatment modalities. Adverse effects are substantially less common and severe compared to CPAP-associated nasal congestion, skin breakdown, or claustrophobic intolerance.

Patient Selection and Candidacy

Optimal candidates for mandibular advancement device therapy include:

  • Patients with mild-to-moderate OSA (AHI 5-30) who are unable or unwilling to tolerate CPAP
  • Patients with simple snoring without OSA who desire treatment
  • Patients with severe OSA as adjunctive therapy to CPAP or when CPAP proves inadequate
  • Patients with limited mandibular advancement capacity requiring assessment for tongue-retaining device or combined therapy
Suboptimal candidates include:
  • Patients with extensive prior dental work (multiple crowns, implants) affecting appliance fit, though modern appliances often accommodate such dentition
  • Patients with severe TMJ disorder precluding mandibular movement
  • Patients with severe retrognathia (severe micrognathia limiting forward positioning capacity)
  • Patients unable to comply with nightly appliance use

Clinical Implementation: Diagnostic and Therapeutic Stages

Proper management of OSA with dental appliances requires collaboration with primary care or sleep medicine physicians for diagnosis, followed by dental management. The diagnostic phase includes sleep study (polysomnography) documenting OSA severity and establishing indication for treatment. The therapeutic phase then proceeds through device fabrication, titration, and follow-up monitoring.

Device fabrication requires detailed dental impressions or scans, with custom appliances constructed from patient-specific models. Appliance delivery involves comprehensive patient instruction regarding insertion, removal, cleaning, and nightly use. Patients must understand that therapeutic benefit requires consistent nightly useβ€”occasional or intermittent use provides insufficient benefit.

The titration phase involves periodic advancement of the mandible (typically at 2-week intervals) until either therapeutic benefit is achieved or patient tolerance limits are reached. Follow-up sleep studies (titration polysomnography) establish whether appliance advancement has produced adequate therapeutic response (typically targeting AHI reduction to <5 or <50% of baseline).

Long-term Monitoring and Compliance

Long-term successful MAD therapy depends on sustained patient compliance with nightly use and regular dental monitoring. Studies indicate that 70-80% of patients continue MAD use long-term, substantially higher compliance rates than CPAP therapy (50-60% compliance). However, 20-30% of patients discontinue devices within 1-2 years, necessitating assessment for reasons (inadequate efficacy, intolerance) and potential alternative therapy.

Regular dental monitoring intervals (6 months initially, then annually) should assess appliance fit and integrity, screen for dental side effects, and reinforce patient compliance. Repeat sleep studies (annually or every 2-3 years) assess whether therapeutic benefit is maintained and whether disease progression or weight gain requires appliance re-titration.

Conclusion

Mandibular advancement devices and tongue-retaining devices represent effective alternative treatments for snoring and obstructive sleep apnea, with demonstrated efficacy comparable to CPAP in mild-to-moderate disease and utility as adjunctive therapy in severe disease. The superior tolerance and compliance characteristics of dental appliances compared to CPAP, combined with their effectiveness and reversibility, position them as essential components of comprehensive OSA management. Dental practitioners play a critical role in patient education regarding available options, appliance fabrication and titration, and long-term monitoring for therapeutic efficacy and adverse effects.